Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer
Conditions
Interventions
Surgery
carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...
+1 more
Locations
5
China
Fudan University Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Fudan University
Shanghai, China
Shanghai Jiao Tong University
Shanghai, China
Start Date
October 18, 2019
Primary Completion Date
June 1, 2025
Completion Date
December 1, 2026
Last Updated
March 18, 2022
NCT06915025
NCT05080946
NCT04657068
NCT05281471
NCT06888921
NCT05445778
Lead Sponsor
Shanghai Gynecologic Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions